Core Viewpoint - The FDA has concluded the inspection of a site involved in BioXcel Therapeutics' TRANQUILITY II trial, indicating that the data from this trial is reliable and supports the company's potential sNDA submission for BXCL501 [1][2] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative medicines in neuroscience using artificial intelligence [5] - The company has a subsidiary, OnkosXcel Therapeutics, which is dedicated to immuno-oncology [5] BXCL501 Overview - BXCL501 is an investigational sublingual film formulation of dexmedetomidine, currently approved as IGALMI by the FDA [3] - It is being investigated for the acute treatment of agitation associated with Alzheimer's dementia and bipolar disorders or schizophrenia in at-home settings [3] - BXCL501 has received Breakthrough Therapy designation for agitation associated with dementia and Fast Track designation for agitation related to schizophrenia and bipolar disorders [3] TRANQUILITY In-Care Phase 3 Trial - The TRANQUILITY In-Care trial is a double-blind, placebo-controlled study evaluating the efficacy and safety of a 60 mcg dose of BXCL501 over 12 weeks for agitation in Alzheimer's dementia patients [4] - The trial aims to enroll approximately 150 patients aged 55 and older with varying degrees of dementia [4] - The primary endpoint is a change in the Positive and Negative Syndrome Scale-Excitatory Component total score at two hours post-first dose [4]

Core Points - BioXcel Therapeutics, Inc. has regained compliance with Nasdaq's minimum closing bid price requirement [1][2] - The company was previously notified on September 16, 2024, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days [2] - To regain compliance, the company needed to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days, which was achieved on February 26, 2025 [2] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience [3] - The company's subsidiary, OnkosXcel Therapeutics, focuses on developing medicines in immuno-oncology [3] - BioXcel employs a drug re-innovation approach, leveraging existing approved drugs and big data with proprietary machine learning algorithms to identify new therapeutic indications [3]

Core Viewpoint - BioXcel Therapeutics, Inc. announced a 1-for-16 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective February 7, 2025 [1][2][5] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 16 shares of common stock into one share, maintaining the par value of $0.001 per share [5] - The reverse stock split was approved by stockholders on January 28, 2025, with a ratio determined by the Board of Directors [5] - Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive a cash payment [3] Group 2: Trading Information - Post-split, the common stock will continue trading on the Nasdaq Capital Market under the symbol "BTAI" with a new CUSIP number [2] - The split-adjusted trading is expected to commence on February 10, 2025 [1] Group 3: Impact on Equity Securities - Proportionate adjustments will be made to the number of shares underlying outstanding stock options and equity incentive plans [4]

Core Insights - BioXcel Therapeutics is advancing its SERENITY and TRANQUILITY clinical programs aimed at treating acute agitation associated with bipolar disorders, schizophrenia, and Alzheimer's dementia, addressing an estimated 140 million annual agitation episodes [2][6] - The company has enhanced its operational and financial flexibility through an amendment to its existing credit agreement and successfully raised $7 million in equity funding [7] - Recent appointments to the Board of Directors have strengthened the company's leadership with expertise in clinical, financial, and legal areas [5][8] Clinical Programs - The SERENITY At-Home Phase 3 trial for BXCL501 is progressing with patient enrollment, focusing on acute treatment for agitation related to bipolar disorders and schizophrenia [1][6] - Plans for the TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer's dementia have been developed [1][6] Financial and Operational Updates - The company has improved its financial position by amending its credit agreement, which was announced on November 25, 2024 [7] - The recent equity funding raised $7 million in gross proceeds, which closed on the same date [7] Leadership Enhancements - The Board of Directors has been strengthened with new members who bring significant operational and clinical expertise, including Dr. Rajiv Patni and David Mack [5][8] - Dr. Rajiv Patni has extensive experience in global product development across various therapeutic areas [5] - David Mack has over 25 years of experience in financial and legal leadership, aiding companies through transitions [8]

Core Viewpoint - The upgrade of BioXcel Therapeutics to a Zacks Rank 2 (Buy) reflects an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [2][8][11]. Earnings Estimates and Revisions - Analysts have raised their earnings estimates for BioXcel Therapeutics, with the Zacks Consensus Estimate increasing by 1.9% over the past three months [5]. - For the fiscal year ending December 2024, BioXcel is expected to report earnings of -$1.80 per share, representing a 70.7% change from the previous year's reported number [13]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [4]. - The Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings across its universe of over 4000 stocks, with only the top 5% receiving a 'Strong Buy' rating [6]. Market Implications - The correlation between earnings estimate revisions and near-term stock movements suggests that tracking these revisions can be beneficial for investment decisions [12]. - The upgrade positions BioXcel Therapeutics in the top 20% of Zacks-covered stocks, indicating its potential for market-beating returns in the near term [15][16].

Core Viewpoint - BioXcel Therapeutics, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $7.0 million before expenses [1][3]. Group 1: Offering Details - The company is offering 5,600,000 shares of common stock and accompanying warrants, with a public offering price of $0.48 per share [1]. - For certain investors, pre-funded warrants to purchase up to 9,000,000 shares are also available, priced at $0.479 per share [1]. - Each accompanying warrant will have an exercise price of $0.48 and will expire five years after issuance [2]. Group 2: Underwriting and Closing - Canaccord Genuity is acting as the sole book-running manager for the public offering [3]. - The offering is expected to close on or about November 25, 2024, subject to customary closing conditions [3]. Group 3: Regulatory Compliance - The securities are being offered under a shelf registration statement filed with the SEC, which became effective on November 13, 2023 [4]. - A preliminary prospectus supplement has been filed with the SEC and is available on their website [4].

Core Viewpoint - BioXcel Therapeutics, Inc. reported a quarterly loss of $0.32 per share, which was better than the Zacks Consensus Estimate of a loss of $0.50, and a significant improvement from a loss of $1.72 per share a year ago, indicating a 36% earnings surprise [1] Financial Performance - The company posted revenues of $0.21 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 82.17%, and a decline from $0.34 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - BioXcel Therapeutics shares have lost about 79% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.49 on revenues of $1.24 million, and for the current fiscal year, it is -$1.97 on revenues of $4.12 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which could impact future stock movements [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Financial Performance - Total revenues for the three months ended September 30, 2023, were $214,000, compared to $341,000 for the same period in 2022, representing a decrease of 37.3%[33]. - Operating expenses for the three months ended September 30, 2023, totaled $15,507,000, a decrease from $48,638,000 in the prior year, reflecting a reduction of 68.1%[33]. - The net loss for the three months ended September 30, 2023, was $13,650,000, compared to a net loss of $50,486,000 for the same period in 2022, indicating a 72.9% improvement[33]. - For the nine months ended September 30, 2024, the company reported a net loss of $48,740, a significant improvement compared to a net loss of $156,797 for the same period in 2023, representing a reduction of approximately 69%[46]. - The company recognized net losses of $13,650 and $50,486 for the three months ended September 30, 2024, and 2023, respectively, showing a 73% improvement in quarterly performance[46]. - Basic and diluted net loss per share for the nine months ended September 30, 2024, was $(1.29), an improvement from $(5.40) in the prior year[195]. Cash and Liquidity - As of September 30, 2024, cash and cash equivalents decreased to $40.387 million from $65.221 million as of December 31, 2023, indicating a decline of approximately 38.1%[30]. - The net cash used in operating activities for the nine months ended September 30, 2024, was $57,218, down from $128,143 in the prior year, indicating a decrease of about 55%[46]. - The company has significant indebtedness, with long-term debt amounting to $104.440 million as of September 30, 2024[31]. - The company has identified conditions that raise substantial doubt about its ability to continue as a going concern[10]. - The Company must maintain a minimum liquidity amount of $15,000, which can increase to $25,000 if certain gross proceeds from stock issuance are not met by September 30, 2024[133]. Debt and Financing - Total liabilities increased to $134.525 million from $130.210 million, reflecting an increase of approximately 3.4%[31]. - The Company entered into two strategic financing agreements providing up to $260,000 in gross funding to support commercial activities and clinical development efforts[115]. - The Company entered into a Second Amendment to the Credit Agreement, providing up to $202,319 in senior secured term loans, including an initial Tranche A of $70,000 funded on April 28, 2022[117]. - The remaining tranches available under the Credit Agreement include Tranche B of $20,000, Tranche C of $30,000, and Tranche D of $50,000, contingent upon meeting specific regulatory and financial milestones[120]. - The Company received $25,000 in gross proceeds from stock issuance on March 27, 2024, satisfying the April 15, 2024 covenant requirement[133]. Research and Development - The company is dependent on the success of IGALMITM and four product candidates: BXCL501, BXCL502, BXCL701, and BXCL702 for future growth[13]. - The company’s most advanced neuroscience clinical development program, BXCL501, is aimed at treating agitation associated with psychiatric and neurological disorders[42]. - The company’s immuno-oncology asset, BXCL701, is under investigation for treating a rare form of prostate cancer and advanced solid tumors[43]. - The Company recognizes research and development expenses as incurred, which include wages, benefits, and costs related to clinical trials[90]. Operational Challenges - The company has incurred significant operating losses since inception and anticipates continuing to incur substantial losses for the foreseeable future[8]. - The regulatory approval processes for product candidates are lengthy and unpredictable, which could substantially harm the business if approvals are not obtained[14]. - The company relies on third parties for the manufacture of clinical supplies and commercial supplies, which poses risks to its operations[22]. - Management has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements due to significant losses and negative cash flows[48]. Stock and Equity - The Company raised $32,687 from the issuance of common stock and warrants during the nine months ended September 30, 2024, compared to $24,657 in the same period of 2023, marking an increase of approximately 32%[46]. - The Company amended and restated the Original Warrants, reducing the exercise price from $20.04 to $3.6452 per share, and granted new warrants for 70 shares at the same exercise price[136]. - The Company recorded a fair value adjustment resulting in an unrealized gain of $16,412 for the nine months ended September 30, 2024, related to derivative liabilities[144]. - The Company had common stock equivalents outstanding of 16,222 shares as of September 30, 2024, compared to 5,688 shares in 2023[194]. Cost Management - Operating expenses for the three months ended September 30, 2023, totaled $15,507,000, a decrease from $48,638,000 in the prior year, reflecting a reduction of 68.1%[33]. - The total stock-based compensation expense recognized for the three months ended September 30, 2024, was $1,865, down from $4,014 in the same period of 2023[173]. - The Company recorded total restructuring costs of $4,163 for the year ended December 31, 2023, which included severance and benefit costs of $4,063 and contract termination costs of $100[104]. Strategic Focus - The company is focused on utilizing AI approaches to develop transformative medicines, aiming to reduce therapeutic development costs and accelerate timelines[39]. - BioXcel Therapeutics, Inc. focuses on developing transformative medicines in neuroscience and immuno-oncology using artificial intelligence[204]. - The company employs AI platforms to reduce therapeutic development costs and potentially accelerate development timelines[204]. - BioXcel aims to leverage existing approved drugs and big data to identify new therapeutic indications, addressing substantial unmet medical needs[204].

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer Rob Risinger - Chief Medical Officer, Neuroscience Conference Call Participants Matt Wiley - Senior Vice President and Chief Commercial Officer Frank Yocca - Chief Scientific Officer Operator Good morning, and wel ...

[Company Overview and Strategic Updates](index=1&type=section&id=Company%20Overview%20and%20Strategic%20Updates) BioXcel Therapeutics is advancing BXCL501's clinical development for agitation in various neurological conditions and strengthening its intellectual property portfolio [Introduction and Strategic Focus](index=1&type=section&id=Introduction%20and%20Strategic%20Focus) BioXcel Therapeutics is focusing on the clinical development of BXCL501, advancing pivotal Phase III trials for acute treatment of agitation associated with bipolar disorder, schizophrenia (outpatient), and Alzheimer's disease (inpatient), aiming to expand market potential - The company continues to focus on the clinical development of BXCL501, advancing the SERENITY At-Home trial (for outpatient treatment of acute agitation associated with bipolar disorder or schizophrenia) and the TRANQUILITY In-Care trial (for agitation associated with Alzheimer's disease)[2](index=2&type=chunk) - The company is committed to meeting the needs of patients, caregivers, and healthcare providers, and sees significant market expansion potential for its primary neuroscience asset[2](index=2&type=chunk) [Clinical Development Updates](index=1&type=section&id=Clinical%20Development%20Updates) The company has made progress on the BXCL501 program, initiating the SERENITY At-Home trial, receiving FDA feedback for the TRANQUILITY In-Care trial, and supporting new investigator-sponsored trials [BXCL501 Pivotal Phase 3 Trials](index=1&type=section&id=BXCL501%20Pivotal%20Phase%203%20Trials) The company has initiated the SERENITY At-Home trial and received FDA feedback for the TRANQUILITY In-Care trial for BXCL501 - The SERENITY At-Home trial has randomized its first patient for acute treatment of agitation associated with bipolar disorder or schizophrenia, with the trial expected to last 9 to 12 months[3](index=3&type=chunk) - The TRANQUILITY In-Care trial has received FDA feedback on the BXCL501 protocol for treating agitation associated with Alzheimer's disease, with the company submitting the protocol on September 5, 2024[3](index=3&type=chunk) [BXCL501 Investigator-Sponsored Trials](index=1&type=section&id=BXCL501%20Investigator-Sponsored%20Trials) The Department of Defense has awarded a grant to fund a Phase IIa trial of BXCL501 for acute stress disorder - The U.S. Department of Defense awarded a grant to the University of North Carolina at Chapel Hill to fund a Phase IIa efficacy and safety trial of BXCL501 for acute stress disorder[4](index=4&type=chunk) - Patient enrollment for this trial is expected to begin in the first half of 2025, marking the second externally funded stress-related trial[4](index=4&type=chunk) [Patent Portfolio](index=1&type=section&id=Patent%20Portfolio) BioXcel Therapeutics continues to strengthen its intellectual property portfolio for IGALMI™ (dexmedetomidine) sublingual film, currently holding 12 Orange Book-listed patents valid until 2037-2043, with a new patent granted until 2043 - The company currently holds **12 Orange Book-listed patents** for IGALMI™, with validities ranging from **2037 to 2043**[5](index=5&type=chunk) - A recent U.S. Patent (U.S. Patent No. 12,138,247) for IGALMI™ was granted, valid until **January 12, 2043**, and is expected to be eligible for Orange Book listing[5](index=5&type=chunk) [Third Quarter 2024 Financial Performance](index=2&type=section&id=Third%20Quarter%202024%20Financial%20Performance) The company significantly reduced its net loss in Q3 2024 due to substantial decreases in R&D and SG&A expenses, despite a quarterly decline in IGALMI net revenue [Key Financial Highlights](index=2&type=section&id=Key%20Financial%20Highlights) BioXcel Therapeutics reported a significantly reduced net loss in Q3 2024, primarily due to substantial decreases in R&D and SG&A expenses following strategic reprioritization and workforce reductions, despite a decline in quarterly net revenue for IGALMI - Net loss for Q3 2024 was **$13.7 million**, a significant reduction from **$50.5 million** in the same period of 2023[10](index=10&type=chunk) - Research and development expenses and selling, general and administrative expenses significantly decreased due to reprioritization in August 2023 and workforce reductions in May 2024[8](index=8&type=chunk)[9](index=9&type=chunk) - IGALMI net revenue for Q3 2024 was **$0.214 million**, lower than **$0.341 million** in Q3 2023, but net revenue for the nine months ended September 30, 2024, increased by **89% to $1.9 million** year-over-year[6](index=6&type=chunk) [Detailed Financial Results](index=2&type=section&id=Detailed%20Financial%20Results) The company experienced a sequential decline in Q3 2024 product revenue, but significant cumulative revenue growth over nine months, while successfully reducing operating expenses through cuts in R&D and SG&A, thereby narrowing its net loss [Net Revenue](index=2&type=section&id=Net%20Revenue) IGALMI net revenue declined in Q3 2024 due to reordering schedules but showed strong growth over the nine-month period IGALMI Net Revenue | Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | | :----- | :--------------------- | :--------------------- | :--------- | | Net Revenue | $214 | $341 | -37.2% | | **Nine Months Ended Sep 30** | | | | | Net Revenue | $1,900 | $1,004 | +89.2% | - The decline in Q3 sales was primarily due to the timing of reorders from existing customers[6](index=6&type=chunk) - The nine-month sales growth reflects new customer acquisition and increased sales activities, indicating higher utilization[6](index=6&type=chunk) [Cost of Goods Sold](index=2&type=section&id=Cost%20of%20Goods%20Sold) Cost of goods sold increased in Q3 2024, primarily due to higher provisions for excess or obsolete inventory Cost of Goods Sold | Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | | :----- | :--------------------- | :--------------------- | :--------- | | Cost of Goods Sold | $1,170 | $512 | +128.5% | - The increase in cost of goods sold was primarily due to higher provisions for excess or obsolete inventory in Q3 2024 compared to the same period in 2023[7](index=7&type=chunk) [Research and Development (R&D) Expenses](index=2&type=section&id=Research%20and%20Development%20(R%26D)%20Expenses) R&D expenses significantly decreased in Q3 2024 due to reduced clinical trial costs, professional services, and personnel expenses R&D Expenses | Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | | :----- | :--------------------- | :--------------------- | :--------- | | R&D Expenses | $5,101 | $19,619 | -74.0% | - The decrease in R&D expenses was primarily due to reduced clinical trial costs, professional service fees, and personnel and related costs resulting from the company's reprioritization in August 2023 and workforce reductions in May 2024[8](index=8&type=chunk) [Selling, General and Administrative (SG&A) Expenses](index=2&type=section&id=Selling%2C%20General%20and%20Administrative%20(SG%26A)%20Expenses) SG&A expenses significantly decreased in Q3 2024 due to reduced personnel, professional services, and commercial expenses SG&A Expenses | Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | | :----- | :--------------------- | :--------------------- | :--------- | | SG&A Expenses | $7,683 | $24,344 | -68.4% | - The decrease in SG&A expenses was primarily due to reduced personnel and related costs resulting from the company's reprioritization in August 2023 and workforce reductions in May 2024, as well as lower professional service fees and commercial expenses[9](index=9&type=chunk) [Net Loss and Cash Position](index=2&type=section&id=Net%20Loss%20and%20Cash%20Position) The company reported a significantly reduced net loss in Q3 2024, with operating cash outflow and a closing cash balance of $40.4 million Net Loss | Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | | :----- | :--------------------- | :--------------------- | :--------- | | Net Loss | $(13,650) | $(50,486) | -73.0% | - Operating cash outflow for Q3 2024 was **$16.3 million**[10](index=10&type=chunk) - Cash and cash equivalents totaled **$40.4 million** as of September 30, 2024[10](index=10&type=chunk) [Product and Company Information](index=2&type=section&id=Product%20and%20Company%20Information) This section provides essential information on IGALMI™ and the investigational drug BXCL501, along with an overview of BioXcel Therapeutics' AI-driven biopharmaceutical approach [About IGALMI™ (dexmedetomidine) sublingual film](index=2&type=section&id=About%20IGALMI%E2%84%A2%20(dexmedetomidine)%20sublingual%20film) IGALMI™ is an FDA-approved prescription sublingual film for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults, requiring administration under healthcare provider supervision with attention to potential serious side effects [INDICATION](index=2&type=section&id=INDICATION) IGALMI™ is indicated for acute agitation in adults with schizophrenia or bipolar disorder, with safety and efficacy not studied beyond 24 hours or in children - IGALMI™ (dexmedetomidine) sublingual film is a prescription medicine used under the supervision of a healthcare provider for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults[13](index=13&type=chunk) - The safety and effectiveness of IGALMI™ have not been studied beyond 24 hours after the first dose or in children[13](index=13&type=chunk) [IMPORTANT SAFETY INFORMATION](index=3&type=section&id=IMPORTANT%20SAFETY%20INFORMATION) IGALMI™ carries important safety information regarding potential serious side effects like hypotension and bradycardia, and contraindications for patients with certain cardiac conditions - IGALMI™ may cause serious side effects, including low blood pressure, orthostatic hypotension, and slow heart rate, which may be more common in patients with hypovolemia, diabetes, chronic hypertension, and the elderly[14](index=14&type=chunk) - IGALMI™ should not be given to patients with abnormal heart rhythms, a history of irregular heartbeats, slow heart rate, low potassium, low magnesium, or those taking other medications that may affect heart rhythm, as it may increase the risk of Torsades de Pointes and sudden death[14](index=14&type=chunk) - Common side effects include somnolence/drowsiness, oral paresthesia or numbness, dizziness, dry mouth, hypotension, and orthostatic hypotension[15](index=15&type=chunk) - Patients should inform their healthcare provider about their medical history, pregnancy or breastfeeding status, and all medications they are taking[16](index=16&type=chunk) [About BXCL501 (Investigational Drug)](index=4&type=section&id=About%20BXCL501%20(Investigational%20Drug)) BXCL501 is an investigational dexmedetomidine oral film, distinct from the approved IGALMI™ indications, currently being studied for acute treatment of agitation associated with Alzheimer's disease dementia and bipolar I or II disorder or schizophrenia in an at-home setting, and has received FDA Breakthrough Therapy and Fast Track designations - BXCL501 is an investigational proprietary oral film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist[18](index=18&type=chunk) - BXCL501 is being studied by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer's disease dementia, and for acute at-home treatment of agitation associated with bipolar I or II disorder or schizophrenia[18](index=18&type=chunk) - BXCL501 has received FDA Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorder, and dementia[18](index=18&type=chunk) [About BioXcel Therapeutics, Inc.](index=4&type=section&id=About%20BioXcel%20Therapeutics%2C%20Inc.) BioXcel Therapeutics is a biopharmaceutical company leveraging artificial intelligence to develop transformative neuroscience drugs, with its wholly-owned subsidiary OnkosXcel Therapeutics focusing on immuno-oncology drug development. The company employs a drug re-innovation approach, combining big data and proprietary machine learning algorithms to identify new therapeutic indications for existing or clinically validated product candidates - BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop transformative drugs in neuroscience[19](index=19&type=chunk) - Its wholly-owned subsidiary, OnkosXcel Therapeutics, focuses on the development of immuno-oncology drugs[19](index=19&type=chunk) - The company employs a drug re-innovation approach, utilizing existing approved drugs and/or clinically validated product candidates, combined with big data and proprietary machine learning algorithms, to identify new therapeutic indications[19](index=19&type=chunk) [Additional Information](index=2&type=section&id=Additional%20Information) This section provides important disclosures regarding forward-looking statements, details on the Q3 2024 earnings conference call, and company contact information [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements regarding future events and company performance, which are subject to various risks and uncertainties that could cause actual results to differ materially from expectations - This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, intended to be covered by the safe harbor provisions[20](index=20&type=chunk) - Forward-looking statements are based on the company's current expectations and various assumptions but are inherently uncertain, and actual results may differ materially from those described or implied due to various important factors[20](index=20&type=chunk) - Important factors include but are not limited to: limited operating history, significant losses, need for substantial additional funding, significant indebtedness, substantial doubt about ability to continue as a going concern, limited drug discovery and development experience, risks related to the TRANQUILITY program, reliance on IGALMI™ and other product candidates, potential overestimation of market size, lack of drug marketing and sales experience, regulatory requirements, preliminary data not predicting final results, ability to obtain regulatory approvals, patient enrollment, adverse side effects, novel approach based on EvolverAI, significant influence and reliance on BioXcel LLC, patent infringement litigation, reliance on third parties, ability to comply with applicable regulations, impact of data breaches or cyberattacks, increased scrutiny related to environmental, social, and governance (ESG) matters, risks related to federal, state or foreign healthcare 'fraud and abuse' laws, and ability to commercialize its product candidates[20](index=20&type=chunk) [Conference Call and Webcast](index=2&type=section&id=Conference%20Call%20and%20Webcast) BioXcel Therapeutics held a conference call and webcast on November 14, 2024, to discuss its third-quarter financial results, providing access details and replay information, and noting the company website as a channel for important information - BioXcel Therapeutics held a conference call and webcast on **November 14, 2024, at 8:00 AM ET**, to discuss its Q3 2024 financial results[11](index=11&type=chunk) - The conference call could be accessed by dialing **877-407-5795** or **201-689-8722**, or via webcast on the investor section of the company's website bioxceltherapeutics.com, with a replay available for 90 days[11](index=11&type=chunk) - The company may use its website as a channel for distributing important company information[12](index=12&type=chunk) [Contact Information](index=6&type=section&id=Contact%20Information) Contact information for BioXcel Therapeutics' company/investor relations and media inquiries is provided - Company/Investor Contact: Erik Kopp, BioXcel Therapeutics, Phone: **1.203.494.7062**[21](index=21&type=chunk) - Media Contact: David Schull, Russo Partners, Phone: **1.858.717.2310**[21](index=21&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) This section presents the unaudited consolidated statements of operations and condensed balance sheets for the specified periods [Statements of Operations](index=7&type=section&id=Statements%20of%20Operations) This section presents the unaudited consolidated statements of operations for the three and nine months ended September 30, 2024, and 2023, detailing the company's revenues, operating expenses, net loss, and net loss per share BioXcel Therapeutics, Inc. Statements of Operations (Unaudited, in thousands, except per share amounts) | Revenues | Three months ended Sep 30, 2024 | Three months ended Sep 30, 2023 | Nine months ended Sep 30, 2024 | Nine months ended Sep 30, 2023 | | :-------------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Product revenues | $214 | $341 | $1,900 | $1,004 | | Operating expenses | | | | | | Cost of goods sold | 1,170 | 512 | 1,311 | 546 | | Research and development | 5,101 | 19,619 | 24,534 | 74,392 | | Selling, general and administrative | 7,683 | 24,344 | 30,398 | 73,810 | | Restructuring costs | 1,553 | 4,163 | 2,409 | 4,163 | | Total operating expenses | 15,507 | 48,638 | 58,652 | 152,911 | | Loss from operations | (15,293) | (48,297) | (56,752) | (151,907) | | Other (income) expense | | | | | | Interest expense, net | 3,790 | 3,252 | 11,097 | 9,879 | | Interest income | (616) | (1,068) | (2,234) | (4,703) | | Other (income) expense, net | (4,817) | 0 | (16,875) | (286) | | Net loss and comprehensive loss | $(13,650) | $(50,486) | $(48,740) | $(156,797) | | Net loss per share - basic and diluted | $(0.32) | $(1.72) | $(1.29) | $(5.40) | | Weighted average shares outstanding - basic and diluted | 42,390 | 29,268 | 37,853 | 29,026 | [Condensed Balance Sheets](index=7&type=section&id=Condensed%20Balance%20Sheets) This section provides unaudited condensed balance sheet data as of September 30, 2024, and December 31, 2023, including cash and cash equivalents, total assets, total liabilities, and total stockholders' equity (deficit) BioXcel Therapeutics, Inc. Condensed Balance Sheets (Unaudited, in thousands) | Metric | September 30, 2024 | December 31, 2023 | | :----------------------------------- | :----------------- | :---------------- | | Cash and cash equivalents | $40,387 | $65,221 | | Total assets | $48,892 | $73,702 | | Total liabilities | $134,525 | $130,210 | | Total stockholders' equity (deficit) | $(85,633) | $(56,508) |